SecBot SecBot

CRMD drug pipeline

CorMedix Inc. · 3 rated drugs
$4.82
+3.4% 1-day · Nov 16
Next catalyst
2026
rezafungin NDA filing
Typical move on FDA news
±4.6%
1-day, median of 5 events
IV rank
No data
No current options data
Rated drugs
3
1 bullish · 2 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

1 dated
  1. 2026
    rezafungin
    NDA filing · prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseApproved
Time to marketAlready marketed (approved March 2023). The supplemental indication for prophylaxis has a PDUFA target in Q1 2027, with a promotional launch targeted for H2 2027 if approved.

rezafungin Updated Oct 24

2026
Next catalyst
NDA filing · 2026 · prophylaxis of invasive fungal diseases in adult patients undergoing allogeneic hematopoietic stem cell transplantation
What to watch

Watch for the specific PDUFA date announcement (Q1 2027) for the REZZAYO prophylaxis sNDA, which is the next major binary catalyst. The stock trades at ~$7.85 with ~$15.33 analyst target (95% upside) but carries ~20% short interest, suggesting a potential squeeze setup if the sNDA is approved. Monitor Q3 earnings on Nov 11, 2026 for REZZAYO revenue trajectory in the currently approved indications.

Bull case
  • REZZAYO is already FDA-approved (March 2023) for candidemia and invasive candidiasis, de-risking the platform. The sNDA for prophylaxis of invasive fungal disease was granted FDA Priority Review in October 2026 with a PDUFA target in Q1 2027, a major label expansion catalyst within ~3-5 months.
  • Analyst consensus is overwhelmingly bullish: 11 buy/strong buy, 1 hold, 0 sell, with a mean price target of $15.33 vs current ~$7.85, implying ~95% upside. Needham reiterated Buy on Oct 19, 2026, and Oppenheimer initiated at Outperform on Sep 23, 2026.
  • Phase III ReSPECT data met its primary endpoint (non-inferior fungal-free survival at Day 90), and the drug showed a favorable safety profile with fewer toxicity-related discontinuations and drug-drug interactions vs standard therapy.
Bear case
  • High short interest (~19.79% of estimated shares outstanding as of Sep 30, 2026) and elevated FINRA short-volume ratio (~57% over 61 sessions) indicate heavy bearish positioning that could reflect skepticism about the prophylaxis expansion opportunity or competitive pressure from cheaper generic echinocandins (micafungin, caspofungin).
  • The Q1 2027 PDUFA is a binary event, if FDA issues a Complete Response Letter or requests additional data for the prophylaxis sNDA, the stock could sell off sharply given the high expectations baked into analyst targets of $15+.
  • The Phase III ReSPECT trial showed 60.7% fungal-free survival at Day 90 for rezafungin vs 59.0% for standard therapy, a narrow 1.7 percentage point margin that may not convince FDA reviewers of meaningful superiority over existing prophylaxis options.
● neutral
Impact
PhaseNot stated
Time to marketNot stated

DefenCath taurolidine and heparin Updated Nov 13

What to watch

DefenCath is already approved and generating revenue, so the next major swing factor is the 2027 Medicare pass-through payment rate, which DaVita warned could drop sharply. Watch for CMS rate-setting updates in early 2027 and the company's Q4 2026 earnings call for 2027 guidance on DefenCath specifically. The Heron acquisition diversifies revenue but adds integration risk.

Bull case
  • DefenCath is the first and only FDA-approved antimicrobial catheter lock solution in the United States, giving it a unique market position with no direct FDA-approved competitor.
  • The Phase 3 LOCK-IT-100 trial showed DefenCath reduced catheter-related bloodstream infections by up to 71% versus heparin alone, a clinically meaningful benefit for a vulnerable patient population.
  • Analyst consensus is strongly bullish: 11 analysts rate the stock with 7 buy and 4 strong buy ratings, with a mean price target of $15.60 (234.8% implied upside from the current ~$4.66 price).
Bear case
  • DaVita CFO warned of a sharp drop in the Medicare add-on payment for DefenCath from Q1 2027 to Q2 2027, which could significantly reduce per-patient reimbursement and slow adoption. The stock hit a fresh 52-week low of $4.65 on this news.
  • Management deferred 2027 guidance for DefenCath on the Q3 2026 earnings call, creating uncertainty about the product's revenue trajectory.
  • CorMedix's Q3 2026 revenue was lower year-over-year as DefenCath entered a new reimbursement period, and the company reported a net loss of $14.7 million for the quarter.
● neutral
Impact
PhaseApproved
Time to marketAlready on the market. Minocin for Injection has been FDA-approved since at least 2015 (newer formulation) and was originally approved in the 1970s.

Minocin minocycline Updated Nov 11

What to watch

Minocin is already approved and commercialized with no upcoming binary catalyst. The next events for CRMD are Q3 2026 earnings (Nov 12, 2026) and the Rezzayo sNDA PDUFA (Q1 2027), but neither is specific to Minocin. The key thing to watch is whether the Heron Therapeutics asset acquisition (announced Nov 9, 2026) closes as expected in 2027 and how Minocin revenue trends as part of the broader Melinta portfolio.

Bull case
  • Minocin is an FDA-approved, commercially established IV antibiotic (minocycline) with patent protection upheld by the Federal Circuit in June 2026, barring Nexus Pharmaceuticals from launching a generic version before patent expiration.
  • The Melinta acquisition (closed Sept 2025) added Minocin and six other marketed products to CorMedix's portfolio, diversifying revenue beyond DefenCath and creating a multi-product acute-care company.
  • Analyst consensus is strongly bullish: 11 of 12 analysts rate Buy or Strong Buy, with a mean price target of $15.40 (190.6% upside from the $5.30 close).
Bear case
  • Minocin is a small part of a larger portfolio; CorMedix's main revenue driver is DefenCath, which faces a post-TDAPA reimbursement reset in 2027 that could materially reduce revenue.
  • The stock trades near its 52-week low ($5.10) and short-sale volume is elevated (66% on Nov 11, 2026), indicating persistent bearish sentiment.
  • CorMedix faces integration risk from two large acquisitions (Melinta in 2025 and Heron in 2026) and has not yet proven a second growth engine beyond DefenCath.

Past FDA events & how the stock moved

5 events
DateDrugEvent1 day5 days
Oct 19, 2026rezafunginPriority review+4.3%—
Jul 1, 2026rezafunginNDA filed+11.5%+10.4%
Apr 27, 2026rezafunginBreakthrough designation+2.0%+6.5%
Jan 1, 2026rezafunginNDA filed+4.6%−35.4%
Nov 15, 2023DefenCathApproval+21.4%+16.9%